Prevalence of APC and PTEN Alterations in Urachal Cancer

1.

Schubert GE, Pavkovic MB, Bethke-Bedurftig BA (1982) Tubular urachal remnants in adult bladders. J Urol 127(1):40–42

CAS  Article  Google Scholar 

2.

Amin MB, Smith SC, Eble JN, Rao P, Choi WWL, Tamboli P, Young RH (2014) Glandular neoplasms of the urachus: a report of 55 cases emphasizing mucinous cystic tumors with proposed classification. Am J Surg Pathol 38(8):1033–1045. https://doi.org/10.1097/PAS.0000000000000250

Article  PubMed  Google Scholar 

3.

Kumar N, Khosla D, Kumar R, Mandal AK, Saikia UN, Kapoor R, Singh SK, Sharma SC (2014) Urachal carcinoma: clinicopathological features, treatment and outcome. J Cancer Res Ther 10(3):571–574. https://doi.org/10.4103/0973-1482.137955

Article  PubMed  Google Scholar 

4.

Reis H, Krafft U, Niedworok C, Módos O, Herold T, Behrendt M, al-Ahmadie H, Hadaschik B, Nyirady P, Szarvas T (2018) Biomarkers in Urachal Cancer and Adenocarcinomas in the Bladder: A Comprehensive Review Supplemented by Own Data. Dis Markers:7308168. https://doi.org/10.1155/2018/7308168

5.

Szarvas T, Modos O, Niedworok C et al (2016) Clinical, prognostic, and therapeutic aspects of urachal carcinoma-a comprehensive review with meta-analysis of 1,010 cases. Urol Oncol 34(9):388–398. https://doi.org/10.1016/j.urolonc.2016.04.012

Article  PubMed  Google Scholar 

6.

Riva G, Mian C, Luchini C, Girolami I, Ghimenton C, Cima L, Novelli L, Hanspeter E, Mazzoleni G, Schwienbacher C, Pycha S, D’Elia C, Trenti E, Pycha A, Martignoni G, Hes O, Eccher A, Nesi G, Brunelli M (2019) Urachal carcinoma: from gross specimen to morphologic, immunohistochemical, and molecular analysis. Virchows Arch 474(1):13–20. https://doi.org/10.1007/s00428-018-2467-1

Article  PubMed  Google Scholar 

7.

Reis H, van der Vos KE, Niedworok C, Herold T, Módos O, Szendrői A, Hager T, Ingenwerth M, Vis DJ, Behrendt MA, de Jong J, van der Heijden MS, Peyronnet B, Mathieu R, Wiesweg M, Ablat J, Okon K, Tolkach Y, Keresztes D, Nagy N, Bremmer F, Gaisa NT, Chlosta P, Kriegsmann J, Kovalszky I, Timar J, Kristiansen G, Radzun HJ, Knüchel R, Schuler M, Black PC, Rübben H, Hadaschik BA, Schmid KW, van Rhijn BWG, Nyirády P, Szarvas T (2018) Pathogenic and targetable genetic alterations in 70 urachal adenocarcinomas. Int J Cancer 143:1764–1773. https://doi.org/10.1002/ijc.31547

CAS  Article  PubMed  Google Scholar 

8.

Modos O, Reis H, Niedworok C et al (2016) Mutations of KRAS, NRAS, BRAF, EGFR, and PIK3CA genes in urachal carcinoma: Occurence and prognostic significance. Oncotarget 7(26):39293–39301. https://doi.org/10.18632/oncotarget.9828

Article  PubMed  PubMed Central  Google Scholar 

9.

Kardos J, Wobker SE, Woods ME, Nielsen ME, Smith AB, Wallen EM, Pruthi RS, Hayward MC, McGinty KA, Grilley-Olson JE, Patel NM, Weck KE, Black P, Parker JS, Milowsky MI, Hayes DN, Kim WY (2017) Comprehensive molecular characterization of Urachal adenocarcinoma reveals commonalities with colorectal Cancer, including a Hypermutable phenotype. JCO Prec Oncol 1(1):1–12. https://doi.org/10.1200/po.17.00027

Article  Google Scholar 

10.

Lee S, Lee J, Sim SH, Lee Y, Moon KC, Lee C, Park WY, Kim NKD, Lee SH, Lee H (2017) Comprehensive somatic genome alterations of urachal carcinoma. J Med Genet 54(8):572–578. https://doi.org/10.1136/jmedgenet-2016-104390

CAS  Article  PubMed  Google Scholar 

11.

Hang JF, Pan CC (2017) Absence of GNAS and BRAF mutations but presence of KRAS mutation in urachal adenocarcinoma. Pathology. 49(3):316–317. https://doi.org/10.1016/j.pathol.2016.11.017

CAS  Article  PubMed  Google Scholar 

12.

Sirintrapun SJ, Ward M, Woo J, Cimic A (2014) High-stage urachal adenocarcinoma can be associated with microsatellite instability and KRAS mutations. Hum Pathol 45(2):327–330. https://doi.org/10.1016/j.humpath.2013.09.008

CAS  Article  PubMed  Google Scholar 

13.

Loh KP, Mondo E, Hansen EA, Sievert L, Fung C, Sahasrabudhe DM, Guancial E (2016) Targeted therapy based on tumor genomic analyses in metastatic Urachal carcinoma. Clin Genitourin Cancer 14(4):e449–e452. https://doi.org/10.1016/j.clgc.2016.03.013

Article  PubMed  Google Scholar 

14.

Collazo-Lorduy A, Castillo-Martin M, Wang L, Patel V, Iyer G, Jordan E, al-Ahmadie H, Leonard I, Oh WK, Zhu J, McBride RB, Cordon-Cardo C, Solit DB, Sfakianos JP, Galsky MD (2016) Urachal Carcinoma Shares Genomic Alterations with Colorectal Carcinoma and May Respond to Epidermal Growth Factor Inhibition. Eur Urol 70(5):771–775. https://doi.org/10.1016/j.eururo.2016.04.037

Article  PubMed  PubMed Central  Google Scholar 

15.

Cha S, Lee J, Shin JY, Kim JY, Sim SH, Keam B, Kim TM, Kim DW, Heo DS, Lee SH, Kim JI (2016) Clinical application of genomic profiling to find druggable targets for adolescent and young adult (AYA) cancer patients with metastasis. BMC Cancer 16:170. https://doi.org/10.1186/s12885-016-2209-1

CAS  Article  PubMed  PubMed Central  Google Scholar 

16.

Singh H, Liu Y, Xiao X et al (2016) Whole exome sequencing of urachal adenocarcinoma reveals recurrent NF1 mutations. Oncotarget 7(20):29211–29215. https://doi.org/10.18632/oncotarget.8640

Article  PubMed  PubMed Central  Google Scholar 

17.

Cancer Genome Atlas N (2012) Comprehensive molecular characterization of human colon and rectal cancer. Nature. 487(7407):330–337. https://doi.org/10.1038/nature11252

CAS  Article  Google Scholar 

18.

Cornejo KM, Paner GP, Tomaszewicz K et al (2016) Mutational profile using next generation sequencing may aid in distinguishing Urachal adenocarcinoma from bladder adenocarcinoma nature modern pathology, 105th annual meeting of the United States and Canadian academy of pathology (USCAP), 2015, Seattle. Washington. 29:528–556. https://doi.org/10.1038/modpathol.2016.25

Article  Google Scholar 

19.

Roy S, Smith MA, Cieply KM, Acquafondata MB, Parwani AV (2012) Primary bladder adenocarcinoma versus metastatic colorectal adenocarcinoma: a persisting diagnostic challenge. Diagn Pathol 7:151. https://doi.org/10.1186/1746-1596-7-151

Article  PubMed  PubMed Central  Google Scholar 

20.

Aoki K, Taketo MM (2007) Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene. J Cell Sci 120(19):3327–3335. https://doi.org/10.1242/jcs.03485

CAS  Article  PubMed  Google Scholar 

21.

Yazdani Y, Farazmandfar T, Azadeh H, Zekavatian Z (2016) The prognostic effect of PTEN expression status in colorectal cancer development and evaluation of factors affecting it: miR-21 and promoter methylation. J Biomed Sci 23:9. https://doi.org/10.1186/s12929-016-0228-5

CAS  Article  PubMed  PubMed Central  Google Scholar 

22.

Frattini M, Saletti P, Romagnani E, Martin V, Molinari F, Ghisletta M, Camponovo A, Etienne LL, Cavalli F, Mazzucchelli L (2007) PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients. Br J Cancer 97(8):1139–1145. https://doi.org/10.1038/sj.bjc.6604009

CAS  Article  PubMed  PubMed Central  Google Scholar 

23.

Sheldon CA, Clayman RV, Gonzalez R, Williams RD, Fraley EE (1984) Malignant urachal lesions. J Urol 131(1):1–8

CAS  Article  Google Scholar 

24.

Toubaji A, Jordan EJ, Desai N et al (2016) Genomic Alterations in Primary Bladder Adenocarcinoma and Urachal Adenocarcinoma. Nature Modern Pathology, 106th Annual Meeting of the United States and Canadian Academy of Pathology (USCAP), 2016, San Antonio, Texas. 30:539. https://doi.org/10.1038/modpathol.2016.265

25.

Pires-Luis A, Martinek P, Filipovic J et al (2018) Primary adenocarcinoma of the urinary bladder: next-generation sequencing (NGS) of non-urachal enteric-type adenocarcinomas, Urachal adenocarcinomas, mucinous adenocarcinomas, and colonic Metaplasias/adenomas. Drugs Future 43:359. https://doi.org/10.1358/dof.2018.043.05.2808557

Article  Google Scholar 

26.

Lee B, Jordan E, Won H, Bagrodia A, Desai N, Bajorin D, Rosenberg J, Bochner B, Kim W, Berger M, Solit D, al-Ahmadie H, Iyer G (2016) Mutational landscape of primary bladder and Urachal adenocarcinoma. J Urol 195(4S):e1133–e11e4. https://doi.org/10.1016/j.juro.2016.02.2431

Article  Google Scholar 

27.

Wong SZ, Lo E, Lee K et al (2004) Prognostic and diagnostic significance of ß-catenin nuclear Immunostaining in colorectal Cancer. Clin Cancer Res 10(4):1401–1408. https://doi.org/10.1158/1078-0432.CCR-0157-03

CAS  Article  PubMed  Google Scholar 

28.

Alomar SY, Mansour L, Abuderman A, Alkhuriji A, Arafah M, Alwasel S, Harrath AH, Almutairi M, Trayhyrn P, Dar JA (2016) β-Catenin accumulation and S33F mutation of CTNNB1 gene in colorectal cancer in Saudi Arabia. Pol J Pathol 67(2):156–162. https://doi.org/10.5114/pjp.2016.61452

CAS  Article  PubMed  Google Scholar 

29.

Perrone F, Lampis A, Orsenigo M, di Bartolomeo M, Gevorgyan A, Losa M, Frattini M, Riva C, Andreola S, Bajetta E, Bertario L, Leo E, Pierotti MA, Pilotti S (2009) PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients. Ann Oncol 20(1):84–90. https://doi.org/10.1093/annonc/mdn541

CAS  Article  PubMed  Google Scholar 

留言 (0)

沒有登入
gif